相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
Mario Luca Morieri et al.
DIABETES OBESITY & METABOLISM (2019)
GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
Marco Castellana et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Liana K. Billings et al.
DIABETES CARE (2018)
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
Hermione Price et al.
DIABETES OBESITY & METABOLISM (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database
Liyue Tong et al.
DIABETES OBESITY & METABOLISM (2018)
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial
H. W. Rodbard et al.
DIABETIC MEDICINE (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
Sultan Linjawi et al.
DIABETES THERAPY (2017)
Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
Louise Vedtofte et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
Stewart B. Harris et al.
DIABETES OBESITY & METABOLISM (2017)
Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
B. Cariou
DIABETES & METABOLISM (2016)
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes The DUAL V Randomized Clinical Trial
Ildiko Lingvay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
Eugene Hughes
PRIMARY CARE DIABETES (2016)
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
Sanjoy K. Paul et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
John B. Buse et al.
DIABETES CARE (2014)
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
R. Balena et al.
DIABETES OBESITY & METABOLISM (2013)
Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
Helen Berlie et al.
DIABETES METABOLIC SYNDROME AND OBESITY (2012)
分享论文
